Improving the Lives of Patients with Alpha-1 Antitrypsin Deficiency

References

• American Thoracic Society/European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900.14522813
   PubMed Web of Science ®Google Scholar
• DeMeoDL, SilvermanEK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1) antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax. 2004;59(3):259–264. doi:10.1136/thx.2003.00650214985567
   PubMed Web of Science ®Google Scholar
• SilvaD, OliveiraMJ, GuimarãesM, et al. Alpha-1-antitrypsin (SERPINA1) mutation spectrum: three novel variants and haplotype characterization of rare deficiency alleles identified in Portugal. Respir Med. 2016;116:8–18. doi:10.1016/j.rmed.2016.05.00227296815
   PubMed Web of Science ®Google Scholar
• StollerJK, LacbawanFL, AboussouanLS Alpha-1 antitrypsin deficiency. GeneReviews® [Internet]; 2006 Available from https://www.ncbi.nlm.nih.gov/books/NBK1519/. Accessed 120, 2020.
   Google Scholar
• CrystalRG. Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest. 1990;85(5):1343–1352. doi:10.1172/JCI1145782185272
   PubMed Web of Science ®Google Scholar
• McCarthyC, ReevesEP, McElvaneyNG. The role of neutrophils in alpha-1 antitrypsin deficiency. Ann Am Thorac Soc. 2016;13(Supplement 4):S297–S304. doi:10.1513/AnnalsATS.201509-634KV27564664
   PubMed Web of Science ®Google Scholar
• NeedhamM, StockleyRA. Exacerbations in alpha-1 antitrypsin deficiency. Eur Respir J. 2005;25(6):992–1000. doi:10.1183/09031936.05.0007470415929953
   PubMed Web of Science ®Google Scholar
• HorváthI, CanotilhoM, ChlumskýJ, et al. Diagnosis and management of alpha-1 antitrypsin deficiency in Europe: an expert survey. ERJ Open Res. 2019;5(1):1–11. doi:10.1183/23120541.00171-2018
   Google Scholar
• Torres-DuránM, Lopez-CamposJL, BarrechegurenM, et al. Alpha-1 antitrypsin deficiency: outstanding questions and future directions. Orphanet J Rare Dis. 2018;13(1):114.29996870
   PubMed Web of Science ®Google Scholar
• EsquinasC, BarrechegurenM, SucenaM, et al. Practice and knowledge about diagnosis and treatment of alpha-1 antitrypsin deficiency in Spain and Portugal. BMC Pulm Med. 2016;16:64. doi:10.1186/s12890-016-0222-4
   Web of Science ®Google Scholar
• GreulichT, OttavianiS, BalsR, et al. Alpha1-antitrypsin deficiency – diagnostic testing and disease awareness in Germany and Italy. Respir Med. 2013;107(9):1400–1408. doi:10.1016/j.rmed.2013.04.02323786890
   PubMed Web of Science ®Google Scholar
• GreulichT, VogelmeierCF. Alpha-1 antitrypsin deficiency: increasing awareness and improving diagnosis. Ther Adv Respir Dis. 2016;10(1):72–84. doi:10.1177/175346581560216226341117
   PubMed Web of Science ®Google Scholar
• AboussouanLS, StollerJK. Detection of alpha-1 antitrypsin deficiency: a review. Respir Med. 2009;103(3):335–341. doi:10.1016/j.rmed.2008.10.00619013782
   PubMed Web of Science ®Google Scholar
• ChapmanKR, BurdonJGW, PiitulainenE, et al. Intravenous augmentation treatment and lung density in severe alpha-1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9991):360–368. doi:10.1016/S0140-6736(15)60860-126026936
   PubMed Web of Science ®Google Scholar
• McElvaneyNG, BurdonJ, HolmesM, et al. Long-term efficacy and safety of alpha-1 proteinase inhibitor treatment for emphysema caused by severe alpha-1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med. 2017;5(1):51–60. doi:10.1016/S2213-2600(16)30430-127916480
   PubMed Web of Science ®Google Scholar
• LonghurstHJ, CarrS, KhairK. C1-inhibitor concentrate home therapy for hereditary angioedema: a viable, effective treatment option. Clin Exp Immunol. 2007;147(1):11–17.17177958
   PubMed Web of Science ®Google Scholar
• SchrijversLH, Beijlevelt-van der ZandeM, PetersM, SchuurmansMJ, FischerK. Learning intravenous infusion in haemophilia: experience from the Netherlands. Haemophilia. 2012;18(4):516–520. doi:10.1111/j.1365-2516.2012.02752.x22292416
   PubMed Web of Science ®Google Scholar
• LeviM, ChoiG, PicavetC, et al. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol. 2006;117(4):904–908. doi:10.1016/j.jaci.2006.01.00216630950
   PubMed Web of Science ®Google Scholar
• Martinez-SaguerI, RusickeE, Aygören-PürsünE, et al. Individual replacement therapy with a pasteurized C1-inhibitor concentrate compared to prophylaxis with danazol in patients with hereditary angioedema - a prospective study. J Allergy Clin Immunol. 2006;117(2):S180. doi:10.1016/j.jaci.2005.12.717
   Web of Science ®Google Scholar
• RusickeE, Martinez-SaguerI, Aygören-PürsünE, et al. Home treatment in patients with hereditary angiodema. J Allergy Clin Immunol. 2006;117(2):S180
   Web of Science ®Google Scholar
• BurgeS, WedzichaJA. COPD exacerbations: definitions and classifications. Eur Respir J. 2003;21(Supplement 41):46s–53s. doi:10.1183/09031936.03.00078002
   Web of Science ®Google Scholar
• AnzuetoA. Impact of exacerbations on COPD. Eur Respir Rev. 2010;19(116):113. doi:10.1183/09059180.0000261020956179
   PubMedGoogle Scholar
• SeemungalTAR, HurstJR, WedzichaJA. Exacerbation rate, health status and mortality in COPD - a review of potential interventions. Int J Chron Obstruct Pulmon Dis. 2009;4:203–223. doi:10.2147/COPD.S338519554195
   PubMedGoogle Scholar
• SeemungalTAR, DonaldsonGC, PaulEA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157(5):1418–1422. doi:10.1164/ajrccm.157.5.97090329603117
   PubMed Web of Science ®Google Scholar
• HillAT, CampbellEJ, BayleyDL, et al. Evidence for excessive bronchial inflammation during an acute exacerbation of chronic obstructive pulmonary disease in patients with α 1 -antitrypsin deficiency (PiZ). Am J Respir Crit Care Med. 1999;160(6):1968–1975. doi:10.1164/ajrccm.160.6.990409710588615
   PubMed Web of Science ®Google Scholar
• DowsonLJ, GuestPJ, StockleyRA. Longitudinal changes in physiological, radiological, and health status measurements in alpha-1 antitrypsin deficiency and factors associated with decline. Am J Respir Crit Care Med. 2001;164(10):1805–1809. doi:10.1164/ajrccm.164.10.210603611734427
   PubMed Web of Science ®Google Scholar
• VijayasarathaK, StockleyRA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest. 2008;133(1):34–41. doi:10.1378/chest.07-169217989153
   PubMed Web of Science ®Google Scholar
• EjioforSI, StolkJ, FernandezP, et al. Patterns and characterization of COPD exacerbations using real-time data collection. Int J Chron Obstruct Pulmon Dis. 2017;12:427–434.28182151
   PubMed Web of Science ®Google Scholar
• StockleyRA, O’BrienC, PyeA, et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest. 2000;117(6):1638–1645. doi:10.1378/chest.117.6.163810858396
   PubMed Web of Science ®Google Scholar
• DirksenA, PiitulainenE, ParrDG, et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha-1 antitrypsin deficiency. Eur Respir J. 2009;33(6):1345–1353. doi:10.1183/09031936.0015940819196813
   PubMed Web of Science ®Google Scholar
• StiverHG, TroskySK, CoteDD, et al. Self-administration of intravenous antibiotics: an efficient, cost-effective home care program. Can Med Assoc J. 1982;127(3):207–211.6809305
   PubMed Web of Science ®Google Scholar
• ConcolinoD, AmicoL, CappelliniMD, et al. Home infusion program with enzyme replacement therapy for Fabry disease: the experience of a large Italian collaborative group. Mol Genet Metab Rep. 2017;12:85–91. doi:10.1016/j.ymgmr.2017.06.00528702361
   PubMed Web of Science ®Google Scholar
• GardulfA, NicolayU. Replacement IgG therapy and self-therapy at home improve the health-related quality of life in patients with primary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2006;6(6):434–442. doi:10.1097/01.all.0000246619.49494.4117088648
   PubMed Web of Science ®Google Scholar
• KhairK, MeerabeauL, GibsonF. Self-management and skills acquisition in boys with haemophilia. Health Expect. 2015;18(5):1105–1113. doi:10.1111/hex.1208323711015
   PubMed Web of Science ®Google Scholar
• BygumA, AndersenKE, MikkelsenCS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009;19(2):147–151.19264579
   PubMed Web of Science ®Google Scholar
• SchmaierAH. The hereditary angioedema syndromes. J Clin Invest. 2019;129(1):66–68. doi:10.1172/JCI12537830530986
   PubMed Web of Science ®Google Scholar
• ZanichelliA, AzinGM, CristinaF, et al. Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study. Orphanet J Rare Dis. 2018;13(1):51. doi:10.1186/s13023-018-0797-329631595
   PubMed Web of Science ®Google Scholar
• SandhausRA, BoydBS. Alpha-1 antitrypsin therapy: a satisfaction survey of individuals self-administering. Am J Respir Crit Care Med. 2018;A1758–A1758.
   Web of Science ®Google Scholar
• Electronic Medicines Compendium. Respreeza SmPC; 2015 Available from https://www.medicines.org.uk/emc/product/7026/smpc. Accessed 120, 2020.
   Google Scholar
• BorkK, Aygören-PürsünE, BasM, et al. Guideline: hereditary angioedema due to C1 inhibitor deficiency. Allergo J Int. 2019;28(1):16–29. doi:10.1007/s40629-018-0088-5
   Google Scholar
• ShapiroRS, ZacekL. Training hereditary angioedema patients to self-administer intravenous C1 esterase inhibitor concentrate. J Infus Nurs. 2014;37(4):284–290. doi:10.1097/NAN.000000000000004924983261
   PubMedGoogle Scholar
• SpruitMA, PittaF, McAuleyE, et al. Pulmonary rehabilitation and physical activity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(8):924–933. doi:10.1164/rccm.201505-0929CI26161676
   PubMed Web of Science ®Google Scholar
• SpruitMA, SinghSJ, GarveyC, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188(8):e13–e64. doi:10.1164/rccm.201309-1634ST24127811
   PubMed Web of Science ®Google Scholar
• VanfleterenLEGW, SpruitMA, GroenenM, et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2013;187(7):728–735. doi:10.1164/rccm.201209-1665OC23392440
   PubMed Web of Science ®Google Scholar
• BeierJ, KirstenA-M, MrózR, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled phase IIIb study. COPD. 2013;10(4):511–522. doi:10.3109/15412555.2013.81462623819698
   PubMedGoogle Scholar
• CasaburiR, HamiltonAL, MerrillDD, et al. Influence of spirometric impairment on improvement in constant work rate cycling endurance in COPD patients: differences in response to bronchodilator therapy and exercise training. Am Thorac Soc. 2019;A4275–A4275.
   Google Scholar
• KennK, GloecklR, SoennichsenA, et al. Predictors of success for pulmonary rehabilitation in patients awaiting lung transplantation. Transplantation. 2015;99(5):1072–1077. doi:10.1097/TP.000000000000047225393161
   PubMed Web of Science ®Google Scholar
• JaroschI, GehlertS, JackoD, et al. Different training-induced skeletal muscle adaptations in COPD patients with and without alpha-1 antitrypsin deficiency. Respiration. 2016;92(5):339–347. doi:10.1159/00044950927686000
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Effects of different exercise training modalities in alpha-1 antitrypsin deficiency patients. Available from https://clinicaltrials.gov/ct2/show/NCT3802357. Accessed 1120, 2019.
   Google Scholar
• MarciniukDD, HernandezP, BalterM, et al. Alpha-1 antitrypsin deficiency targeted testing and augmentation therapy: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2012;19(2):109–116. doi:10.1155/2012/92091822536580
   PubMed Web of Science ®Google Scholar
• ScholsAM, FerreiraIM, FranssenFM, et al. Nutritional assessment and therapy in COPD: a European respiratory society statement. Eur Respir J. 2014;44(6):1504. doi:10.1183/09031936.0007091425234804
   PubMed Web of Science ®Google Scholar